![]() Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | ![]() Spectrum Pharmaceuticals Spectrum Pharmaceuticals is a biotechnology company developing drugs to treat oncology and hematology. | ![]() Arcus Biosciences Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology. | |||
Founding Date | Founding Date 2014 | Founding Date 2001 | Founding Date 2002 | Founding Date 2015 | Founding Date 2013 |
Type | Type Private | Type Subsidiary | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Rockville, US HQ Pohang, KR Seongnam Si, KR | Locations Gent, BE HQ | Locations Henderson, US HQ Irvine, US | Locations Hayward, US HQ | Locations South San Francisco, US HQ Oss, NL Oss, NL |
Employees | Employees 405% decrease | Employees 1252% decrease | Employees 14638% decrease | Employees 500502% increase | Employees 197 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 211.4 m | Valuation ($) 1.5 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €85.2m (FY, 2016) | Revenue (est.) $10.1m (FY, 2022) | Revenue (est.) $247m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income N/A | Net income (€1.1m) (FY, 2016) | Net income ($75.4m) (FY, 2022) | Net income ($353m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 498.8m | Total funding raised $ 3m | Total funding raised $ 70m | Total funding raised $ 60m |

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company
Spectrum Pharmaceuticals is a biotechnology company developing drugs to treat oncology and hematology.
View company
Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology.
View company